Sophie Lanzkron

TitleProfessor
InstitutionThomas Jefferson University
DepartmentHematology
Address1020 Locust St.
Philadelphia PA 19107
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    K23HL083089     (LANZKRON, SOPHIE M)Mar 1, 2008 - Jan 31, 2014
    NIH
    Sickle Cell Disease: First steps toward understanding barriers to care for adults
    Role: Principal Investigator

    R34HL113438     (LANZKRON, SOPHIE M)Aug 5, 2013 - Jul 31, 2016
    NIH
    Improving Access to Hydroxyurea for Adults with Sickle Cell Disease
    Role: Principal Investigator

    R21HL144973     (LANZKRON, SOPHIE M)Sep 15, 2018 - Aug 31, 2020
    NIH
    Anti-Mullerian Hormone in the Female Participants of the Multi-Center Study of Hydroxyurea
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Anderson AR, Strouse JJ, Manwani D, Brandow AM, Vichinsky EP, Campbell A, Leavey PJ, Nero A, Ibrahim IF, Field JJ, Baer A, Soto-Calderon H, Vincent L, Zhao Y, Santos JJS, Hensley SE, Mortier N, Lanzkron S, Neuberg DS, Abrams CS. COVID-19 mRNA Vaccination Responses in Individuals With Sickle Cell Disease: ASH RC Sickle Cell Research Network Study. Blood Adv. 2024 Jul 11. PMID: 38991137.
      Citations:    
    2. Lanzkron S, Crook N, Wu J, Hussain S, Curtis R, Robertson D, Baker JR, Nugent D, Soni A, Roberts JC, Ullman M, Kanter J, Nichol M. Costs and Impact of Disease in Adults with Sickle Cell Disease: A Pilot Study. Blood Adv. 2024 May 22. PMID: 38776399.
      Citations:    
    3. Kanter J, Ataga KI, Bhasin N, Guarino S, Kutlar A, Lanzkron S, Manwani D, McGann P, Stowell SR, Tubman VN, Yermilov I, Campos C, Broder MS. Expert consensus on the management of infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) receiving crizanlizumab: a RAND/UCLA modified Delphi panel. Ann Hematol. 2024 Jun; 103(6):1909-1917. PMID: 38642304.
      Citations:    
    4. Wen T, Puett RC, Liao D, Kanter J, Mittleman MA, Lanzkron SM, Yanosky JD. Short-term air pollution levels and sickle cell disease hospital encounters in South Carolina: A case-crossover analysis. Environ Res. 2024 Apr 05; 252(Pt 1):118766. PMID: 38583660.
      Citations:    
    5. Gladwin MT, Gordeuk VR, Desai PC, Minniti C, Novelli EM, Morris CR, Ataga KI, De Castro L, Curtis SA, El Rassi F, Ford HJ, Harrington T, Klings ES, Lanzkron S, Liles D, Little J, Nero A, Smith W, Taylor JG, Baptiste A, Hagar W, Kanter J, Kinzie A, Martin T, Rafique A, Telen MJ, Lalama CM, Kato GJ, Abebe KZ. Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial. Lancet Haematol. 2024 Mar 27. PMID: 38554715.
      Citations:    
    6. Jenkins AM, Lanzkron S, Auger KA. Disparities in pediatric hospital use during transition to adult healthcare for young adults with childhood-onset chronic conditions. J Hosp Med. 2024 Mar 22. PMID: 38517142.
      Citations:    
    7. Sharma D, Kozanoglu I, Ataga KI, Benachi A, B?y?kkurt S, Lanzkron S, Ozdogu H, Pancham S, Pecker LH, Robinson SE, Yilmaz Baran S, Howard J. Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel. Blood Adv. 2024 Feb 27; 8(4):1018-1029. PMID: 38206762.
      Citations:    
    8. Ellis JD, Samiei S, Neupane S, DuPont C, McGill L, Chow P, Lanzkron S, Haythornthwaite J, Campbell CM, Kumar S, Finan PH. Sleep Disruption Moderates the Daily Dynamics of Affect and Pain in Sickle Cell Disease. J Pain. 2024 Jan 18. PMID: 38242332.
      Citations:    
    9. Jonassaint CR, Parchuri E, O'Brien JA, Lalama CM, Lin J, Badawy SM, Hamm ME, Stinson J, Lalloo C, Carroll CP, Saraf SL, Gordeuk VR, Cronin R, Shah N, Lanzkron SM, Liles D, Trimnell C, Bailey L, Lawrence RH, Abebe KZ. Mental health, pain and likelihood of opioid misuse among adults with sickle cell disease. Br J Haematol. 2024 Mar; 204(3):1029-1038. PMID: 38171495.
      Citations:    
    10. Early ML, Raja M, Luo A, Solow M, Matusiak K, Eke AC, Shehata N, Kuo KHM, Lanzkron S, Malinowski AK, Pecker LH. Blood pressure thresholds for the diagnosis of hypertensive disorders of pregnancy in sickle cell disease. Br J Haematol. 2024 Mar; 204(3):1039-1046. PMID: 38093478.
      Citations:    
    11. Mercure-Corriveau N, Crowe EP, Vozniak S, Feng X, Rai H, Van Denakker T, Zakieh A, Grabowski MK, Lanzkron S, Tobian AAR, Bloch EM. Euvolemic automated transfusion to treat severe anemia in sickle cell disease patients at risk of circulatory overload. Transfusion. 2024 01; 64(1):124-131. PMID: 38069526.
      Citations:    
    12. Pecker LH, Akinsete AM, Carroll CP, Lanzkron S, Kuo KHM, Hulbert M, Stenger E, Darbari DS. Life after sickle cell disease, is it really uhuru? Lancet Haematol. 2023 Dec; 10(12):e946-e949. PMID: 38030314.
      Citations:    
    13. Early ML, Luo A, Solow M, Matusiak K, Eke AC, Shehata N, August P, Kuo KHM, Lanzkron S, Malinowski AK, Pecker LH. Natural history of blood pressure in sickle cell disease pregnancy. Br J Haematol. 2024 02; 204(2):658-667. PMID: 37803527.
      Citations:    
    14. Prince E, Loeser P, Early M, Carroll CP, Lanzkron S, Pecker LH. "Buprenorphine, It Works so Differently": Adults with Sickle Cell Disease Describe Transitioning to Buprenorphine for Treatment of Chronic Pain. J Pain. 2024 Mar; 25(3):632-641. PMID: 37742907.
      Citations:    
    15. Pecker LH, Ruvalcaba E, Lanzkron S, Eakin MN. "The Patient Should Have a Choice": Adults with Sickle Cell Disease Advise Integration of Telemedicine into the Comprehensive Sickle Cell Disease Care Model. J Racial Ethn Health Disparities. 2023 Sep 08. PMID: 37682425.
      Citations:    
    16. Pecker LH, Burke A, Streiff MB, Lanzkron S, Naik RP. Progestin-only contraception is first line for sickle cell disease: a comment on "Hormonal therapies in females with blood disorders: thrombophilia, thrombosis, hemoglobinopathies, and anemias." Res Pract Thromb Haemost. 2023 Aug; 7(6):102183. PMID: 37711908.
      Citations:    
    17. Reilly GR, Xie Y, Scherer RW, Hawkins BS, Lanzkron SM, Scott AW. Terminology for Retinal Findings in Sickle Cell Disease Research: A Scoping Review. Ophthalmol Retina. 2024 Jan; 8(1):81-87. PMID: 37634744.
      Citations:    
    18. Kelly DL, Glassman M, Wonodi I, Vyas G, Richardson CM, Nwulia E, Wehring HJ, Oduguwa T, Mackowick M, Hipolito MMS, Peters O, Rai N, Park J, Adebayo AO, Gorelick DA, Weiner E, Liu F, Kearns AM, Adams HA, Love RC, Chen S, Olaniyan A, Ambulos N, McKoy D, Nallani MC, Lanzkron S, Mengistab M, Barr B, Davis E, Lawal R, Buchanan RW, Adebayo R. Clozapine and neutrophil response in patients of African descent: A six-month, multinational, prospective, open-label clinical trial. Schizophr Res. 2023 Aug 24. PMID: 37633776.
      Citations:    
    19. Kenney MO, Wilson S, Shah N, Bortsov A, Smith WR, Little J, Lanzkron S, Kanter J, Padrino S, Owusu-Ansah A, Cohen A, Desai P, Manwani D, Rehman SSU, Hagar W, Keefe F. Biopsychosocial Factors Associated With Pain and Pain-Related Outcomes in Adults and Children With Sickle Cell Disease: A Multivariable Analysis of the GRNDaD Multicenter Registry. J Pain. 2024 Jan; 25(1):153-164. PMID: 37544393.
      Citations:    
    20. Chaturvedi S, Yu J, Brown J, Wei A, Selvakumar S, Gerber GF, Moliterno AR, Streiff MB, Kraus P, Logue CM, Yui JC, Naik RP, Latif H, Lanzkron SM, Braunstein EM, Brodsky RA, Gottesman RF, Lin DD. Silent cerebral infarction during immune TTP remission: prevalence, predictors, and impact on cognition. Blood. 2023 07 27; 142(4):325-335. PMID: 37216688.
      Citations:    
    21. Guarino SH, Williams KD, Caplan RJ, Fawcett M, Lanzkron S. COVID-19 in hospitalized adult patients with sickle cell disease: A 2020 US cohort using Cerner Real-World Data? (CRWD). J Clin Transl Sci. 2023; 7(1):e152. PMID: 37528938.
      Citations:    
    22. Carrithers B, Raja M, Gemmill A, Cayton Vaught KC, Christianson MS, Lanzkron S, Pecker LH. Knowledge of fertility and perception of fertility treatment among adults with sickle cell disease (KNOW FERTILITY). Front Glob Womens Health. 2023; 4:1191064. PMID: 37360321.
      Citations:    
    23. Prince EJ, Pecker LH, Lanzkron S, Carroll CP. The Complex Association of Daily Opioid Dose with Visits for Pain in Sickle Cell Disease: Tolerance or Treatment-Refractory Pain? Pain Med. 2023 06 01; 24(6):703-712. PMID: 36458906.
      Citations:    
    24. Azbell RCG, Lanzkron SM, Desai PC. Current Evidence and Rationale to Guide Perioperative Management, Including Transfusion Decisions, in Patients With Sickle Cell Disease. Anesth Analg. 2023 06 01; 136(6):1107-1114. PMID: 37205803.
      Citations:    
    25. Linton EA, Williams EC, Early ML, Prince E, Stewart RW, Lanzkron S, Pecker LH. Family planning needs of young adults with sickle cell disease. EJHaem. 2023 Aug; 4(3):587-594. PMID: 37601884.
      Citations:    
    26. Early ML, Eke AC, Gemmill A, Lanzkron S, Pecker LH. Comparisons of Severe Maternal Morbidity and Other Adverse Pregnancy Outcomes in Pregnant People With Sickle Cell Disease vs Anemia. JAMA Netw Open. 2023 02 01; 6(2):e2254545. PMID: 36729453.
      Citations:    
    27. Early ML, Eke AC, Gemmill A, Lanzkron S, Pecker LH. Severe Maternal Morbidity and Mortality in Sickle Cell Disease in the National Inpatient Sample, 2012-2018. JAMA Netw Open. 2023 02 01; 6(2):e2254552. PMID: 36729452.
      Citations:    
    28. Pecker LH, Oteng-Ntim E, Nero A, Lanzkron S, Christianson MS, Woolford T, Meacham LR, Mishkin AD. Expecting more: the case for incorporating fertility services into comprehensive sickle cell disease care. Lancet Haematol. 2023 Mar; 10(3):e225-e234. PMID: 36708736.
      Citations:    
    29. Costa V, Mercure-Corriveau N, Gourneau J, Tobian AAR, Jones JM, Lauriello A, Lanzkron S, Crowe EP, Bloch EM. Transfusion-transmitted babesiosis in a patient with sickle cell disease undergoing chronic red cell exchange. Transfusion. 2023 03; 63(3):652-655. PMID: 36637364.
      Citations:    
    30. Guarino S, Lanzkron S. Evidence-Based Minireview: How to utilize new therapies for sickle cell disease. Hematology Am Soc Hematol Educ Program. 2022 Dec 09; 2022(1):283-285. PMID: 36485112.
      Citations:    
    31. Lanzkron S, Little J. Sickle Cell Disease: New Approaches for an Old Disease. Hematol Oncol Clin North Am. 2022 Dec; 36(6):xiii-xiv. PMID: 36400546.
      Citations:    
    32. McGill LS, Hamilton KR, Letzen JE, Finan PH, Lanzkron SM, Smith MT, Haythornthwaite JA, Campbell CM. Depressive and Insomnia Symptoms Sequentially Mediate the Association Between Racism-Based Discrimination in Healthcare Settings and Clinical Pain Among Adults With Sickle Cell Disease. J Pain. 2023 04; 24(4):643-654. PMID: 36414154.
      Citations:    
    33. Zhang S, Xue W, Boorman EP, Ruvalcaba E, David M, Lanzkron SM, Eakin MN. Accessible Care with High Patient Satisfaction: Telemedicine Use in Sickle Cell Disease. Telemed J E Health. 2023 Jul; 29(7):1068-1077. PMID: 36394473.
      Citations:    
    34. Guarino S, Wright CS, Pachter LM, Lanzkron SM. Peer Mediated Groups:: Nonpharmacologic Management of Pain for and By Those with Sickle Cell Disease. Dela J Public Health. 2022 Oct; 8(4):8-11. PMID: 36340952.
      Citations:    
    35. David MS, Jones J, Lauriello A, Nnake I, Plazas Montana M, Lasko K, Buri-Nagua C, Olagbaju Y, Williams E, Sears M, Salzberg B, Lanzkron SM, Carroll CP. Converting adults with sickle cell disease from full agonist opioids to buprenorphine: A reliable method with safety and early evidence of reduced acute care utilization. Am J Hematol. 2022 Nov; 97(11):1435-1442. PMID: 36053825.
      Citations:    
    36. Christian J, Lanzkron S, Naik RP. COVID-19 outcomes in sickle cell disease and sickle cell trait. Best Pract Res Clin Haematol. 2022 Sep; 35(3):101382. PMID: 36494153.
      Citations:    
    37. Ogunsile FJ, Stewart KJ, Kanter J, Lanzkron SM. An evaluation of cardiopulmonary endurance and muscular strength in adults living with sickle cell disease. Br J Haematol. 2022 11; 199(4):597-602. PMID: 36052816.
      Citations:    
    38. Jones JM, Swett AD, Crowe EP, Lawrence C, Bloch EM, Lanzkron SM. Implementation of national blood conservation recommendations at an adult sickle cell center. Transfusion. 2022 09; 62(9):1763-1771. PMID: 35837727.
      Citations:    
    39. Lanzkron S, Pecker L. Pain without gain: steroids and sickle crisis. Blood. 2022 06 30; 139(26):3678-3679. PMID: 35771559.
      Citations:    
    40. Brucato M, Lance E, Lanzkron S, Wang X, Pecker LH. Developmental disorders in children born to women with sickle cell disease: A report from the Boston Birth Cohort. EJHaem. 2022 Aug; 3(3):894-898. PMID: 36051016.
      Citations:    
    41. Early ML, Linton E, Bosch A, Campbell T, Hill-Briggs F, Pecker LH, Lance EI, Lanzkron S. The Montreal cognitive assessment as a cognitive screening tool in sickle cell disease: Associations with clinically significant cognitive domains. Br J Haematol. 2022 07; 198(2):382-390. PMID: 35385886.
      Citations:    
    42. Guarino S, Wright C, Lanzkron S. Health Care Utilization by Adolescent/Young Adult Patients With Sickle Cell Disease in Delaware. Cureus. 2022 Feb; 14(2):e22700. PMID: 35386169.
      Citations:    
    43. Pecker LH, Hussain S, Mahesh J, Varadhan R, Christianson MS, Lanzkron S. Diminished ovarian reserve in young women with sickle cell anemia. Blood. 2022 02 17; 139(7):1111-1115. PMID: 34864892.
      Citations:    
    44. Lanzkron S, Manwani D, Desai P, Kanter J, Little J. GRNDaD: big data and sickle cell disease. Blood Adv. 2022 02 08; 6(3):1088. PMID: 35133406.
      Citations:    
    45. Kim A, Assarzadegan N, Anders RA, Oshima K, Chaturvedi S, Weeks S, Kohli R, Lanzkron S, Gurakar A, Garonzik-Wang J, Chen PH. Liver Transplant in Hemoglobin SC Disease and Autoimmune Hepatitis: A Case Report. Exp Clin Transplant. 2022 04; 20(4):429-432. PMID: 34981707.
      Citations:    
    46. Lee LH, Whisenton LH, Benger J, Lanzkron S. A community-centered approach to sickle cell disease and clinical trial participation: an evaluation of perceptions, facilitators, and barriers. Blood Adv. 2021 12 14; 5(23):5323-5331. PMID: 34543385.
      Citations:    
    47. Early ML, Strodel RJ, Lake IV, Ruddy JA, Saba JA, Singh SM, Lanzkron S, Mack JW, Meier ER, Christianson MS, Pecker LH. Acceptable, hopeful, and useful: development and mixed-method evaluation of an educational tool about reproductive options for people with sickle cell disease or trait. J Assist Reprod Genet. 2022 Jan; 39(1):183-193. PMID: 34806131.
      Citations:    
    48. Ahmed I, Pradeep T, Goldberg MF, Liu TYA, Aradhya A, Montana MP, Photiadis N, Williams E, Smith B, Tian J, Lanzkron SM, Scott AW. Nonmydriatic Ultra-Widefield Fundus Photography in a Hematology Clinic Shows Utility for Screening of Sickle Cell Retinopathy. Am J Ophthalmol. 2022 04; 236:241-248. PMID: 34780794.
      Citations:    
    49. Wilson SR, Sears M, Williams E, Drapekin J, Sivakumar I, Padrino S, Desai PC, Hager W, Manwani D, Clay LJ, Field JJ, Kanter J, Cohen AJ, Saif Ur Rehman S, Lanzkron S, Little JA. Gaps in the diagnosis and management of iron overload in sickle cell disease: a 'real-world' report from the GRNDaD registry. Br J Haematol. 2021 12; 195(5):e157-e160. PMID: 34423416.
      Citations:    
    50. Chidambaram V, Jones JM, Lokhandwala PM, Bloch EM, Lanzkron S, Stewart R, Pecker LH. Low rates of transfusion-transmitted infection screening in chronically transfused adults with sickle cell disease. Transfusion. 2021 08; 61(8):2421-2429. PMID: 34251034.
      Citations:    
    51. Lanzkron S, Little J, Wang H, Field JJ, Shows JR, Haywood C, Saheed M, Proudford M, Robertson D, Kincaid A, Burgess L, Green C, Seufert R, Brooks J, Piehet A, Griffin B, Arnold N, Frymark S, Wallace M, Abu Al Hamayel N, Huang CY, Segal JB, Varadhan R. Treatment of Acute Pain in Adults With Sickle Cell Disease in an Infusion Center Versus the Emergency Department : A Multicenter Prospective Cohort Study. Ann Intern Med. 2021 09; 174(9):1207-1213. PMID: 34224261.
      Citations:    
    52. Pecker LH, Hussain S, Lanzkron S, Tao X, Thaler K, Burke AE, Whaley N. Women with sickle cell disease report low knowledge and use of long acting reversible contraception. J Natl Med Assoc. 2021 Oct; 113(5):552-559. PMID: 34119338.
      Citations:    
    53. Mun CJ, Finan PH, Smith MT, Carroll CP, Smyth JM, Lanzkron SM, Haythornthwaite JA, Campbell CM. A Preliminary Investigation of the Underlying Mechanism Associating Daily Sleep Continuity Disturbance and Prescription Opioid Use Among Individuals With Sickle Cell Disease. Ann Behav Med. 2021 06 02; 55(6):580-591. PMID: 33196076.
      Citations:    
    54. Desai P, Little J, Kanter J, Bridges K, Andemariam B, Lanzkron S. Kneeling Was the First Step for Sickle Cell Disease. Ann Intern Med. 2021 07; 174(7):1004-1005. PMID: 33750189.
      Citations:    
    55. Bae S, Johnson M, Massie AB, Luo X, Haywood C, Lanzkron SM, Grams ME, Segev DL, Purnell TS. Mortality and Access to Kidney Transplantation in Patients with Sickle Cell Disease-Associated Kidney Failure. Clin J Am Soc Nephrol. 2021 03 08; 16(3):407-414. PMID: 33632759.
      Citations:    
    56. Lanzkron S, Smith-Whitley K. Swaying sickle cell research forward in support of patient reported outcomes. Am J Hematol. 2021 04 01; 96(4):402-403. PMID: 33393092.
      Citations:    
    57. Pecker LH, Lanzkron S. Sickle Cell Disease. Ann Intern Med. 2021 01; 174(1):ITC1-ITC16. PMID: 33428443.
      Citations:    
    58. Kanter J, Smith WR, Desai PC, Treadwell M, Andemariam B, Little J, Nugent D, Claster S, Manwani DG, Baker J, Strouse JJ, Osunkwo I, Stewart RW, King A, Shook LM, Roberts JD, Lanzkron S. Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Adv. 2020 08 25; 4(16):3804-3813. PMID: 32785684.
      Citations:    
    59. Wilson JD, Lanzkron S, Pecker LH, Bediako SM, Han D, Beach MC. Psychosocial and Clinical Risk Factors Associated with Substance Use in Observational Cohort of Patients with Sickle Cell Disease. Subst Use Misuse. 2020; 55(13):2205-2212. PMID: 32762425.
      Citations:    
    60. Pecker LH, Hussain S, Christianson MS, Lanzkron S. Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide. Br J Haematol. 2020 12; 191(5):880-887. PMID: 32712966.
      Citations:    
    61. Wilson JD, Pecker LH, Lanzkron S, Bediako SM, Han D, Beach MC. Marijuana use and health behaviors in a US clinic sample of patients with sickle cell disease. PLoS One. 2020; 15(7):e0235192. PMID: 32663844.
      Citations:    
    62. Campbell A, Cong Z, Agodoa I, Song X, Martinez DJ, Black D, Lew CR, Varker H, Chan C, Lanzkron S. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study. J Manag Care Spec Pharm. 2020 Sep; 26(9):1121-1129. PMID: 32597290.
      Citations:    
    63. Farooq F, Mogayzel PJ, Lanzkron S, Haywood C, Strouse JJ. Comparison of US Federal and Foundation Funding of Research for Sickle Cell Disease and Cystic Fibrosis and Factors Associated With Research Productivity. JAMA Netw Open. 2020 03 02; 3(3):e201737. PMID: 32219405.
      Citations:    
    64. Liem RI, Lanzkron S, D Coates T, DeCastro L, Desai AA, Ataga KI, Cohen RT, Haynes J, Osunkwo I, Lebensburger JD, Lash JP, Wun T, Verhovsek M, Ontala E, Blaylark R, Alahdab F, Katabi A, Mustafa RA. American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Adv. 2019 12 10; 3(23):3867-3897. PMID: 31794601.
      Citations:    
    65. Murad MH, Liem RI, Lang ES, Akl EA, Meerpohl JJ, DeBaun MR, Tisdale JF, Brandow AM, Lanzkron SM, Chou ST, Webb S, Mustafa RA. 2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. Blood Adv. 2019 12 10; 3(23):3945-3950. PMID: 31794603.
      Citations:    
    66. Kanter J, Lanzkron S. Innovations in Targeted Anti-Adhesion Treatment for Sickle Cell Disease. Clin Pharmacol Ther. 2020 01; 107(1):140-146. PMID: 31617585.
      Citations:    
    67. Lubeck D, Agodoa I, Bhakta N, Danese M, Pappu K, Howard R, Gleeson M, Halperin M, Lanzkron S. Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease. JAMA Netw Open. 2019 11 01; 2(11):e1915374. PMID: 31730182.
      Citations:    
    68. Ruhl AP, Sadreameli SC, Allen JL, Bennett DP, Campbell AD, Coates TD, Diallo DA, Field JJ, Fiorino EK, Gladwin MT, Glassberg JA, Gordeuk VR, Graham LM, Greenough A, Howard J, Kato GJ, Knight-Madden J, Kopp BT, Koumbourlis AC, Lanzkron SM, Liem RI, Machado RF, Mehari A, Morris CR, Ogunlesi FO, Rosen CL, Smith-Whitley K, Tauber D, Terry N, Thein SL, Vichinsky E, Weir NA, Cohen RT, Klings ES. Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report. Ann Am Thorac Soc. 2019 09; 16(9):e17-e32. PMID: 31469310.
      Citations:    
    69. Jabour SM, Beachy S, Coburn S, Lanzkron S, Eakin MN. The Role of Patient-Physician Communication on the Use of Hydroxyurea in Adult Patients with Sickle Cell Disease. J Racial Ethn Health Disparities. 2019 12; 6(6):1233-1243. PMID: 31410784.
      Citations:    
    70. Su ZT, Segal JB, Lanzkron S, Ogunsile FJ. National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997-2017. Pharmacoepidemiol Drug Saf. 2019 09; 28(9):1246-1250. PMID: 31328369.
      Citations:    
    71. Merrill SA, Brodsky RA, Lanzkron SM, Naik R. A case-control analysis of hyperhemolysis syndrome in adults and laboratory correlates of complement involvement. Transfusion. 2019 10; 59(10):3129-3139. PMID: 31292968.
      Citations:    
    72. Letzen JE, Lanzkron S, Bond K, Carroll CP, Haythornthwaite JA, Nance S, Campbell CM. Preliminary evidence that hydroxyurea is associated with attenuated peripheral sensitization in adults with sickle cell disease. Pain Rep. 2019 Mar-Apr; 4(2):e724. PMID: 31041423.
      Citations:    
    73. Ogunsile FJ, Naik R, Lanzkron S. Overcoming challenges of venous thromboembolism in sickle cell disease treatment. Expert Rev Hematol. 2019 03; 12(3):173-182. PMID: 30773073.
      Citations:    
    74. Goddu AP, O'Conor KJ, Lanzkron S, Saheed MO, Saha S, Peek ME, Haywood C, Beach MC. Correction to: Do Words Matter? Stigmatizing Language and the Transmission of Bias in the Medical Record. J Gen Intern Med. 2019 Jan; 34(1):164. PMID: 30338470.
      Citations:    
    75. Ogunsile FJ, Bediako SM, Nelson J, Cichowitz C, Yu T, Patrick Carroll C, Stewart K, Naik R, Haywood C, Lanzkron S. Metabolic syndrome among adults living with sickle cell disease. Blood Cells Mol Dis. 2019 02; 74:25-29. PMID: 30391047.
      Citations:    
    76. Ronda J, Nord A, Arrington-Sanders R, Naik R, Takemoto CM, Baskin J, Lanzkron S, Pecker LH. Challenges in the management of the transgender patient with sickle cell disease. Am J Hematol. 2018 11; 93(11):E360-E362. PMID: 30094866.
      Citations:    
    77. Lanzkron S, Sawicki GS, Hassell KL, Konstan MW, Liem RI, McColley SA. Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. J Clin Transl Sci. 2018 Oct; 2(5):334-342. PMID: 30828476.
      Citations:    
    78. Duan XJ, Lanzkron S, Linz MO, Ewing C, Wang J, Scott AW. Clinical and Ophthalmic Factors Associated With the Severity of Sickle Cell Retinopathy. Am J Ophthalmol. 2019 01; 197:105-113. PMID: 30278160.
      Citations:    
    79. Lanzkron S, Little J, Field J, Shows JR, Wang H, Seufert R, Brooks J, Varadhan R, Haywood C, Saheed M, Huang CY, Griffin B, Frymark S, Piehet A, Robertson D, Proudford M, Kincaid A, Green C, Burgess L, Wallace M, Segal J. Increased acute care utilization in a prospective cohort of adults with sickle cell disease. Blood Adv. 2018 09 25; 2(18):2412-2417. PMID: 30254105.
      Citations:    
    80. Pecker LH, Maher JY, Law JY, Beach MC, Lanzkron S, Christianson MS. Risks associated with fertility preservation for women with sickle cell anemia. Fertil Steril. 2018 09; 110(4):720-731. PMID: 30196969.
      Citations:    
    81. Carroll CP, Cichowitz C, Yu T, Olagbaju YO, Nelson JA, Campbell T, Lanzkron S. Predictors of acute care utilization and acute pain treatment outcomes in adults with sickle cell disease: The role of non-hematologic characteristics and baseline chronic opioid dose. Am J Hematol. 2018 09; 93(9):1127-1135. PMID: 30035821.
      Citations:    
    82. Merrill SA, Naik R, Streiff MB, Shanbhag S, Lanzkron S, Braunstein EM, Moliterno AM, Brodsky RA. A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis. Medicine (Baltimore). 2018 Aug; 97(31):e11579. PMID: 30075527.
      Citations:    
    83. Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med. 2018 Jul 19; 379(3):226-235. PMID: 30021096.
      Citations:    
    84. Ter-Minassian M, Lanzkron S, Derus A, Brown E, Horberg MA. Quality Metrics and Health Care Utilization for Adult Patients with Sickle Cell Disease. J Natl Med Assoc. 2019 Feb; 111(1):54-61. PMID: 30129484.
      Citations:    
    85. P Goddu A, O'Conor KJ, Lanzkron S, Saheed MO, Saha S, Peek ME, Haywood C, Beach MC. Do Words Matter? Stigmatizing Language and the Transmission of Bias in the Medical Record. J Gen Intern Med. 2018 05; 33(5):685-691. PMID: 29374357.
      Citations:    
    86. Finan PH, Carroll CP, Moscou-Jackson G, Martel MO, Campbell CM, Pressman A, Smyth JM, Tremblay JM, Lanzkron SM, Haythornthwaite JA. Daily Opioid Use Fluctuates as a Function of Pain, Catastrophizing, and Affect in Patients With Sickle Cell Disease: An Electronic Daily Diary Analysis. J Pain. 2018 01; 19(1):46-56. PMID: 28943232.
      Citations:    
    87. Moon J, Hyland RH, Zhang F, Brainard DM, Lanzkron S, McHutchison JG, Sulkowski M. Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease. Clin Infect Dis. 2017 Sep 01; 65(5):864-866. PMID: 28505305.
      Citations:    
    88. Sood R, Jiramongkolchai K, Streiff M, Gonzalez C, Shanbhag S, Lanzkron S, Arevalo JF, Naik R. Look into my eyes: An unusual first presentation of sickle cell disease. Am J Hematol. 2017 Sep; 92(9):968-971. PMID: 28494508.
      Citations:    
    89. Lanzkron S, Naik RP. Negative studies shape the state of sickle trait. Blood. 2017 02 09; 129(6):661-662. PMID: 28183743.
      Citations:    
    90. Mathur VA, Kiley KB, Haywood C, Bediako SM, Lanzkron S, Carroll CP, Buenaver LF, Pejsa M, Edwards RR, Haythornthwaite JA, Campbell CM. Multiple Levels of Suffering: Discrimination in Health-Care Settings is Associated With Enhanced Laboratory Pain Sensitivity in Sickle Cell Disease. Clin J Pain. 2016 12; 32(12):1076-1085. PMID: 26889615.
      Citations:    
    91. Cichowitz C, Carroll PC, Strouse JJ, Haywood C, Lanzkron S. Utility of the Montreal Cognitive Assessment as a Screening Test for Neurocognitive Dysfunction in Adults with Sickle Cell Disease. South Med J. 2016 09; 109(9):560-5. PMID: 27598362.
      Citations:    
    92. Stewart RW, Whiteman LN, Strouse JJ, Carroll CP, Lanzkron S. Improving Inpatient Care for Individuals with Sickle Cell Disease Using the Project ECHO Model. South Med J. 2016 09; 109(9):568-9. PMID: 27598364.
      Citations:    
    93. Carroll CP, Haywood C, Lanzkron SM. Examination of the Patient and Hospitalization Characteristics of 30-Day SCD Readmissions. South Med J. 2016 09; 109(9):583-7. PMID: 27598369.
      Citations:    
    94. Whiteman LN, Haywood C, Lanzkron S, Strouse JJ, Batchelor AH, Schwartz A, Stewart RW. Effect of Free Dental Services on Individuals with Sickle Cell Disease. South Med J. 2016 09; 109(9):576-8. PMID: 27598367.
      Citations:    
    95. Lanzkron S. Need for Specialized Centers to Provide Acute Care to Adults with Sickle Cell Disease. South Med J. 2016 09; 109(9):566-7. PMID: 27598363.
      Citations:    
    96. Yu T, Campbell T, Ciuffetelli I, Haywood C, Carroll CP, Resar L, Strouse JJ, Lanzkron S. Symptomatic Avascular Necrosis: An Understudied Risk Factor for Acute Care Utilization by Patients with SCD. South Med J. 2016 09; 109(9):519-24. PMID: 27598353.
      Citations:    
    97. Mathur VA, Kiley KB, Carroll CP, Edwards RR, Lanzkron S, Haythornthwaite JA, Campbell CM. Disease-Related, Nondisease-Related, and Situational Catastrophizing in Sickle Cell Disease and Its Relationship With Pain. J Pain. 2016 11; 17(11):1227-1236. PMID: 27555427.
      Citations:    
    98. Razdan S, Strouse JJ, Reddy A, Resar DF, Hasan RK, Resar JR, Naik RP, Urrutia VC, Lanzkron S, Resar LM. Patent foramen ovale in adults with sickle cell disease and stroke. Am J Hematol. 2016 09; 91(9):E358-60. PMID: 27253454.
      Citations:    
    99. Carroll CP, Lanzkron S, Haywood C, Kiley K, Pejsa M, Moscou-Jackson G, Haythornthwaite JA, Campbell CM. Chronic Opioid Therapy and Central Sensitization in Sickle Cell Disease. Am J Prev Med. 2016 07; 51(1 Suppl 1):S69-77. PMID: 27320469.
      Citations:    
    100. Campbell CM, Carroll CP, Kiley K, Han D, Haywood C, Lanzkron S, Swedberg L, Edwards RR, Page GG, Haythornthwaite JA. Quantitative sensory testing and pain-evoked cytokine reactivity: comparison of patients with sickle cell disease to healthy matched controls. Pain. 2016 Apr; 157(4):949-956. PMID: 26713424.
      Citations:    
    101. Yu TT, Nelson J, Streiff MB, Lanzkron S, Naik RP. Risk factors for venous thromboembolism in adults with hemoglobin SC or S?(+) thalassemia genotypes. Thromb Res. 2016 May; 141:35-8. PMID: 26962984.
      Citations:    
    102. Campbell CM, Moscou-Jackson G, Carroll CP, Kiley K, Haywood C, Lanzkron S, Hand M, Edwards RR, Haythornthwaite JA. An Evaluation of Central Sensitization in Patients With Sickle Cell Disease. J Pain. 2016 05; 17(5):617-27. PMID: 26892240.
      Citations:    
    103. Haywood C, Lanzkron S, Hughes M, Brown R, Saha S, Beach MC. The Association of Clinician Characteristics with their Attitudes Toward Patients with Sickle Cell Disease: Secondary Analyses of a Randomized Controlled Trial. J Natl Med Assoc. 2015 Jun; 107(2):89-96. PMID: 27269495.
      Citations:    
    104. Puri Singh A, Haywood C, Beach MC, Guidera M, Lanzkron S, Valenzuela-Araujo D, Rothman RE, Dugas AF. Improving Emergency Providers' Attitudes Toward Sickle Cell Patients in Pain. J Pain Symptom Manage. 2016 Mar; 51(3):628-32.e3. PMID: 26596878.
      Citations:    
    105. Whiteman LN, Haywood C, Lanzkron S, Strouse JJ, Feldman L, Stewart RW. Primary Care Providers' Comfort Levels in Caring for Patients with Sickle Cell Disease. South Med J. 2015 Sep; 108(9):531-6. PMID: 26332477.
      Citations:    
    106. Telen MJ, Wun T, McCavit TL, De Castro LM, Krishnamurti L, Lanzkron S, Hsu LL, Smith WR, Rhee S, Magnani JL, Thackray H. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood. 2015 Apr 23; 125(17):2656-64. PMID: 25733584.
      Citations:    
    107. Lanzkron S, Carroll CP, Hill P, David M, Paul N, Haywood C. Impact of a dedicated infusion clinic for acute management of adults with sickle cell pain crisis. Am J Hematol. 2015 May; 90(5):376-80. PMID: 25639822.
      Citations:    
    108. Savage WJ, Buchanan GR, Yawn BP, Afenyi-Annan AN, Ballas SK, Goldsmith JC, Hassell KL, James AH, John-Sowah J, Jordan L, Lottenberg R, Murad MH, Ortiz E, Tanabe PJ, Ware RE, Lanzkron SM. Evidence gaps in the management of sickle cell disease: A summary of needed research. Am J Hematol. 2015 Apr; 90(4):273-5. PMID: 25639238.
      Citations:    
    109. Lanzkron S, Haywood C. The five key things you need to know to manage adult patients with sickle cell disease. Hematology Am Soc Hematol Educ Program. 2015; 2015:420-5. PMID: 26637752.
      Citations:    
    110. Whiteman LN, Lanzkron S, Stewart RW, Haywood C, Strouse JJ, Feldman L. Quality improvement process in a sickle cell infusion center. Am J Med. 2015 May; 128(5):541-4. PMID: 25498167.
      Citations:    
    111. Naik RP, Derebail VK, Grams ME, Franceschini N, Auer PL, Peloso GM, Young BA, Lettre G, Peralta CA, Katz R, Hyacinth HI, Quarells RC, Grove ML, Bick AG, Fontanillas P, Rich SS, Smith JD, Boerwinkle E, Rosamond WD, Ito K, Lanzkron S, Coresh J, Correa A, Sarto GE, Key NS, Jacobs DR, Kathiresan S, Bibbins-Domingo K, Kshirsagar AV, Wilson JG, Reiner AP. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA. 2014 Nov 26; 312(20):2115-25. PMID: 25393378.
      Citations:    
    112. Haywood C, Lanzkron S, Bediako S, Strouse JJ, Haythornthwaite J, Carroll CP, Diener-West M, Onojobi G, Beach MC. Perceived discrimination, patient trust, and adherence to medical recommendations among persons with sickle cell disease. J Gen Intern Med. 2014 Dec; 29(12):1657-62. PMID: 25205621.
      Citations:    
    113. Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ, Ware RE, Murad MH, Goldsmith JC, Ortiz E, Fulwood R, Horton A, John-Sowah J. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014 Sep 10; 312(10):1033-48. PMID: 25203083.
      Citations:    
    114. Hassell KL, Afenyi-Annan A, Ballas SK, Buchanan GR, Eckman JR, Jordan L, Lanzkron S, Lottenberg R, Ware R. Practice guideline for pulmonary hypertension in sickle cell: direct evidence needed before universal adoption. Am J Respir Crit Care Med. 2014 Jul 15; 190(2):237-8. PMID: 25025359.
      Citations:    
    115. Bediako SM, Lanzkron S, Diener-West M, Onojobi G, Beach MC, Haywood C. The Measure of Sickle Cell Stigma: Initial findings from the Improving Patient Outcomes through Respect and Trust study. J Health Psychol. 2016 05; 21(5):808-20. PMID: 24997169.
      Citations:    
    116. Gladwin MT, Barst RJ, Gibbs JS, Hildesheim M, Sachdev V, Nouraie M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli E, Girgis RE, Morris CR, Berman Rosenzweig E, Badesch DB, Lanzkron S, Castro OL, Taylor JG, Goldsmith JC, Kato GJ, Gordeuk VR, Machado RF. Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom. PLoS One. 2014; 9(7):e99489. PMID: 24988120.
      Citations:    
    117. Haywood C, Lanzkron S, Diener-West M, Haythornthwaite J, Strouse JJ, Bediako S, Onojobi G, Beach MC. Attitudes toward clinical trials among patients with sickle cell disease. Clin Trials. 2014 06; 11(3):275-283. PMID: 24532686.
      Citations:    
    118. Haywood C, Bediako S, Lanzkron S, Diener-West M, Strouse J, Haythornthwaite J, Onojobi G, Beach MC. An unequal burden: poor patient-provider communication and sickle cell disease. Patient Educ Couns. 2014 Aug; 96(2):159-64. PMID: 24935607.
      Citations:    
    119. Abt NB, Streiff MB, Gocke CB, Kickler TS, Lanzkron SM. Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor. Case Rep Hematol. 2014; 2014:484563. PMID: 24955264.
      Citations:    
    120. Haywood C, Diener-West M, Strouse J, Carroll CP, Bediako S, Lanzkron S, Haythornthwaite J, Onojobi G, Beach MC. Perceived discrimination in health care is associated with a greater burden of pain in sickle cell disease. J Pain Symptom Manage. 2014 Nov; 48(5):934-43. PMID: 24742787.
      Citations:    
    121. Naik RP, Streiff MB, Lanzkron S. The reply. Am J Med. 2013 Oct; 126(10):e15. PMID: 24054961.
      Citations:    
    122. Minniti CP, Delaney KM, Gorbach AM, Xu D, Lee CC, Malik N, Koroulakis A, Antalek M, Maivelett J, Peters-Lawrence M, Novelli EM, Lanzkron SM, Axelrod KC, Kato GJ. Vasculopathy, inflammation, and blood flow in leg ulcers of patients with sickle cell anemia. Am J Hematol. 2014 Jan; 89(1):1-6. PMID: 23963836.
      Citations:    
    123. Razdan S, Strouse JJ, Naik R, Lanzkron S, Urrutia V, Resar JR, Resar LM. Patent foramen ovale in patients with sickle cell disease and stroke: case presentations and review of the literature. Case Rep Hematol. 2013; 2013:516705. PMID: 23956892.
      Citations:    
    124. Naik RP, Streiff MB, Haywood C, Nelson JA, Lanzkron S. Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. Am J Med. 2013 May; 126(5):443-9. PMID: 23582935.
      Citations:    
    125. Naik RP, Streiff MB, Lanzkron S. Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. J Thromb Thrombolysis. 2013 Apr; 35(3):352-8. PMID: 23435703.
      Citations:    
    126. Carroll PC, Haywood C, Hoot MR, Lanzkron S. A preliminary study of psychiatric, familial, and medical characteristics of high-utilizing sickle cell disease patients. Clin J Pain. 2013 Apr; 29(4):317-23. PMID: 23246997.
      Citations:    
    127. Lanzkron S, Carroll CP, Haywood C. Mortality rates and age at death from sickle cell disease: U.S., 1979-2005. Public Health Rep. 2013 Mar-Apr; 128(2):110-6. PMID: 23450875.
      Citations:    
    128. Haywood C, Tanabe P, Naik R, Beach MC, Lanzkron S. The impact of race and disease on sickle cell patient wait times in the emergency department. Am J Emerg Med. 2013 Apr; 31(4):651-6. PMID: 23380119.
      Citations:    
    129. Nouraie M, Lee JS, Zhang Y, Kanias T, Zhao X, Xiong Z, Oriss TB, Zeng Q, Kato GJ, Gibbs JS, Hildesheim ME, Sachdev V, Barst RJ, Machado RF, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli E, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Goldsmith JC, Gordeuk VR, Gladwin MT. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica. 2013 Mar; 98(3):464-72. PMID: 22983573.
      Citations:    
    130. Bola?os-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, Brodsky RA. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012 Nov 22; 120(22):4285-91. PMID: 22955919.
      Citations:    
    131. Naik RP, Lanzkron S. Baby on board: what you need to know about pregnancy in the hemoglobinopathies. Hematology Am Soc Hematol Educ Program. 2012; 2012:208-14. PMID: 23233583.
      Citations:    
    132. Strouse JJ, Lanzkron S, Urrutia V. The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease. Expert Rev Hematol. 2011 Dec; 4(6):597-606. PMID: 22077524.
      Citations:    
    133. Tanabe P, Stevenson A, DeCastro L, Drawhorn L, Lanzkron S, Molokie RE, Artz N. Evaluation of a train-the-trainer workshop on sickle cell disease for ED providers. J Emerg Nurs. 2013 Nov; 39(6):539-46. PMID: 21937097.
      Citations:    
    134. Sachdev V, Kato GJ, Gibbs JS, Barst RJ, Machado RF, Nouraie M, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli EM, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Taylor JG, Hannoush H, Goldsmith JC, Gladwin MT, Gordeuk VR. Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom. Circulation. 2011 Sep 27; 124(13):1452-60. PMID: 21900080.
      Citations:    
    135. Carroll CP, Haywood C, Lanzkron S. Prediction of onset and course of high hospital utilization in sickle cell disease. J Hosp Med. 2011 May; 6(5):248-55. PMID: 21661098.
      Citations:    
    136. Machado RF, Barst RJ, Yovetich NA, Hassell KL, Kato GJ, Gordeuk VR, Gibbs JS, Little JA, Schraufnagel DE, Krishnamurti L, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Onyekwere O, Castro OL, Sachdev V, Waclawiw MA, Woolson R, Goldsmith JC, Gladwin MT. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood. 2011 Jul 28; 118(4):855-64. PMID: 21527519.
      Citations:    
    137. Gladwin MT, Kato GJ, Weiner D, Onyekwere OC, Dampier C, Hsu L, Hagar RW, Howard T, Nuss R, Okam MM, Tremonti CK, Berman B, Villella A, Krishnamurti L, Lanzkron S, Castro O, Gordeuk VR, Coles WA, Peters-Lawrence M, Nichols J, Hall MK, Hildesheim M, Blackwelder WC, Baldassarre J, Casella JF. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA. 2011 Mar 02; 305(9):893-902. PMID: 21364138.
      Citations:    
    138. Haywood C, Beach MC, Bediako S, Carroll CP, Lattimer L, Jarrett D, Lanzkron S. Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. Am J Hematol. 2011 Jan; 86(1):85-7. PMID: 21117058.
      Citations:    
    139. Haywood C, Lanzkron S, Hughes MT, Brown R, Massa M, Ratanawongsa N, Beach MC. A video-intervention to improve clinician attitudes toward patients with sickle cell disease: the results of a randomized experiment. J Gen Intern Med. 2011 May; 26(5):518-23. PMID: 21181560.
      Citations:    
    140. Lattimer L, Haywood C, Lanzkron S, Ratanawongsa N, Bediako SM, Beach MC. Problematic hospital experiences among adult patients with sickle cell disease. J Health Care Poor Underserved. 2010 Nov; 21(4):1114-23. PMID: 21099065.
      Citations:    
    141. Lanzkron S, Carroll CP, Haywood C. The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database. Am J Hematol. 2010 Oct; 85(10):797-9. PMID: 20730795.
      Citations:    
    142. Bediako SM, Lattimer L, Haywood C, Ratanawongsa N, Lanzkron S, Beach MC. Religious coping and hospital admissions among adults with sickle cell disease. J Behav Med. 2011 Apr; 34(2):120-7. PMID: 20812027.
      Citations:    
    143. Haywood C, Lanzkron S, Ratanawongsa N, Bediako SM, Lattimer-Nelson L, Beach MC. Hospital self-discharge among adults with sickle-cell disease (SCD): associations with trust and interpersonal experiences with care. J Hosp Med. 2010 May-Jun; 5(5):289-94. PMID: 20533577.
      Citations:    
    144. Haywood C, Lanzkron S, Ratanawongsa N, Bediako SM, Lattimer L, Powe NR, Beach MC. The association of provider communication with trust among adults with sickle cell disease. J Gen Intern Med. 2010 Jun; 25(6):543-8. PMID: 20195785.
      Citations:    
    145. Cavanaugh KL, Lanzkron S. Time to recognize an overlooked trait. J Am Soc Nephrol. 2010 Mar; 21(3):385-6. PMID: 20133485.
      Citations:    
    146. Lanzkron S, Haywood C, Fagan PJ, Rand CS. Examining the effectiveness of hydroxyurea in people with sickle cell disease. J Health Care Poor Underserved. 2010 Feb; 21(1):277-86. PMID: 20173269.
      Citations:    
    147. Haywood C, Beach MC, Lanzkron S, Strouse JJ, Wilson R, Park H, Witkop C, Bass EB, Segal JB. A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease. J Natl Med Assoc. 2009 Oct; 101(10):1022-33. PMID: 19860302.
      Citations:    
    148. Carroll CP, Haywood C, Fagan P, Lanzkron S. The course and correlates of high hospital utilization in sickle cell disease: Evidence from a large, urban Medicaid managed care organization. Am J Hematol. 2009 Oct; 84(10):666-70. PMID: 19743465.
      Citations:    
    149. Strouse JJ, Jordan LC, Lanzkron S, Casella JF. The excess burden of stroke in hospitalized adults with sickle cell disease. Am J Hematol. 2009 Sep; 84(9):548-52. PMID: 19623672.
      Citations:    
    150. Ratanawongsa N, Haywood C, Bediako SM, Lattimer L, Lanzkron S, Hill PM, Powe NR, Beach MC. Health care provider attitudes toward patients with acute vaso-occlusive crisis due to sickle cell disease: development of a scale. Patient Educ Couns. 2009 Aug; 76(2):272-8. PMID: 19233587.
      Citations:    
    151. Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics. 2008 Dec; 122(6):1332-42. PMID: 19047254.
      Citations:    
    152. Lanzkron S, Haywood C, Hassell KL, Rand C. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network. J Natl Med Assoc. 2008 Aug; 100(8):968-73. PMID: 18717150.
      Citations:    
    153. Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008 Jun 17; 148(12):939-55. PMID: 18458272.
      Citations:    
    154. Segal JB, Strouse JJ, Beach MC, Haywood C, Witkop C, Park H, Wilson RF, Bass EB, Lanzkron S. Hydroxyurea for the treatment of sickle cell disease. Evid Rep Technol Assess (Full Rep). 2008 Mar; (165):1-95. PMID: 18457478.
      Citations:    
    155. Liebelt EL, Balk SJ, Faber W, Fisher JW, Hughes CL, Lanzkron SM, Lewis KM, Marchetti F, Mehendale HM, Rogers JM, Shad AT, Skalko RG, Stanek EJ. NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. Birth Defects Res B Dev Reprod Toxicol. 2007 Aug; 80(4):259-366. PMID: 17712860.
      Citations:    
    156. Lanzkron S, Haywood C, Segal JB, Dover GJ. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol. 2006 Dec; 81(12):927-32. PMID: 16924648.
      Citations:    
    157. Laurence B, Woods D, George D, Onyekwere O, Katz R, Lanzkron S, Diener-West M, Powe N. Self-perceived loss of control and untreated dental decay in African American adults with and without sickle cell disease. J Health Care Poor Underserved. 2006 Aug; 17(3):641-51. PMID: 16960327.
      Citations:    
    158. Laurence B, George D, Woods D, Shosanya A, Katz RV, Lanzkron S, Diener-West M, Powe N. The association between sickle cell disease and dental caries in African Americans. Spec Care Dentist. 2006 May-Jun; 26(3):95-100. PMID: 16774185.
      Citations:    
    159. Miller RG, Segal JB, Ashar BH, Leung S, Ahmed S, Siddique S, Rice T, Lanzkron S. High prevalence and correlates of low bone mineral density in young adults with sickle cell disease. Am J Hematol. 2006 Apr; 81(4):236-41. PMID: 16550513.
      Citations:    
    160. Lanzkron S, Moliterno AR, Norris EJ, Gould SA, Segal J, Nuermberger EL, Ness PM. Polymerized human Hb use in acute chest syndrome: a case report. Transfusion. 2002 Nov; 42(11):1422-7. PMID: 12421214.
      Citations:    
    Lanzkron's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (449)
    Explore
    _
    Co-Authors (2)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _